Quick Read
- Novo Nordisk (NVO) stock fell over 14% pre-market on February 23, 2026.
- The decline was triggered by disappointing Phase 3 trial results for its obesity drug, CagriSema.
- CagriSema achieved 23.0% weight loss but failed to match Eli Lilly’s tirzepatide (25.5%).
- NVO stock has fallen 67% from its 2024 peak, partly due to Eli Lilly’s market entry.
- Novo Nordisk is shifting towards oral forms of Ozempic and Wegovy to boost market share.
NEW YORK (Azat TV) – Novo Nordisk A/S (NVO) stock experienced a significant pre-market decline on Monday, February 23, 2026, following the announcement of disappointing headline results from its Redefine 4 Phase 3 clinical trial for CagriSema. The experimental obesity drug failed to meet its primary endpoint against Eli Lilly’s tirzepatide, a development that immediately impacted investor sentiment and raised concerns about Novo Nordisk’s competitive position in the rapidly evolving obesity treatment market.
Shares of the Danish pharmaceutical giant plummeted more than 14% in pre-market trading, reflecting investor anxiety over the trial’s outcome. The news prompted a shift in retail sentiment around Novo Nordisk on platforms like Stocktwits, which trended towards ‘extremely bearish’ at the time of the announcement, underscoring the market’s sensitivity to clinical trial results in this high-stakes sector.
CagriSema Trial Results Trigger NVO Stock Decline
The Redefine 4 trial, an open-label Phase 3 study, evaluated CagriSema as a once-weekly subcutaneous treatment for adults with overweight or obesity. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo Nordisk had stated that the drug induced a 23.0% weight loss after 84 weeks in people with obesity. However, this figure fell short when compared to tirzepatide 15 mg, which demonstrated a 25.5% weight loss over the same period.
When measuring the treatment effect regardless of adherence, CagriSema achieved a 20.2% weight loss, while tirzepatide delivered 23.6%. This direct comparison revealed CagriSema’s inability to match tirzepatide in terms of overall effectiveness, leading to the trial’s failure to meet its primary endpoint. Despite this, Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer and Executive Vice President, commented that CagriSema has the potential to be the first GLP-1/amylin-combination product for obesity, suggesting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to GLP-1 biology alone.
Novo Nordisk’s Position in the Obesity Drug Market
The latest trial results arrive at a critical juncture for Novo Nordisk, which has been a dominant player in the GLP-1 drug market with its products Ozempic (for diabetes) and Wegovy (for weight loss). Ozempic, initially approved in late 2017, saw a significant boost with the introduction of Wegovy for weight loss in 2021, leading to a 60% stock gain for Novo Nordisk that year. By 2023, the company’s sales soared by 35%, and profits jumped by 55%.
However, the competitive landscape intensified in 2024 with Eli Lilly’s entry into the market with its own GLP-1 drugs, Zepbound and Mounjaro. This competition led to a period of decline for Novo Nordisk’s stock, which topped out above $142 in 2024 and subsequently slid to around $47 per share by the close of last week, representing a 67% drop from its peak. Novo Nordisk is currently attempting to regain market share by transitioning from injectable forms of Wegovy and Ozempic to new pill-based versions, with oral Wegovy approved by the FDA in December and oral Ozempic approved last month. This strategic pivot aims to capitalize on convenience and potentially expand market access.
Investor Outlook Amidst NVO Stock Volatility
Despite the recent pre-market downturn and the year-to-date 7% drop (and 46% over the past 12 months), some investors view Novo Nordisk’s current valuation as a potential long-term opportunity. With the stock trading at a price-to-free cash flow (FCF) ratio of less than 23, which is below market average, and FCF projected to grow at 17.5% annually over the next five years, the company’s fundamentals still attract interest. Additionally, Novo Nordisk currently pays a strong 3.8% dividend yield, making it an appealing option for income-focused investors looking past the immediate volatility.
The company’s historical performance demonstrates its ability to innovate and adapt, particularly in the face of competition. While Eli Lilly’s tirzepatide has proven to be a formidable competitor, Novo Nordisk’s proactive shift to oral GLP-1 drugs and its continued investment in research and development, despite setbacks like CagriSema, signal a commitment to maintaining its leadership in the metabolic disease space.
The immediate negative market reaction to the CagriSema trial results highlights the intense scrutiny pharmaceutical companies face in the high-growth obesity drug market, where incremental differences in efficacy can significantly sway investor confidence and market share.